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INTRODUCTION
Hepatocellular carcinoma (HCC) is the second 
leading cause of cancer-related mortality worldwide [1]. 
Resection and transplantation are the only potentially 
curative treatments available following detection of a small 
HCC [2]. For the majority of patients with locally advanced 
disease, however, transarterial embolization and the multi-
kinase inhibitor sorafenib are the only approved treatments. 
Unfortunately, both provide a limited survival benefit [2].
The ubiquitin-proteasome pathway is responsible for 
the degradation of misfolded proteins as well as short-lived 
mediators of signaling pathways regulating cell proliferation 
and survival [3]. Proteasome inhibition leads to the 
accumulation of these substrates, resulting in concomitant 
activation of pro- and antiproliferative signals, disruption of 
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ABSTRACT
Hepatocellular carcinoma (HCC) responds poorly to conventional systemic 
therapies. The first-in-class proteasome inhibitor bortezomib has been approved in 
clinical use for hematologic malignancies and has shown modest activity in solid 
tumors, including HCC. However, a considerable proportion of patients fail to respond 
and experience important adverse events. Recently, the next-generation orally 
bioavailable irreversible proteasome inhibitor oprozomib was developed. Here, we 
assessed the efficacy of oprozomib and its effects on the unfolded protein response 
(UPR), a signaling cascade activated through the ATF6, PERK and IRE1 pathways 
by accumulation of unfolded proteins in the endoplasmic reticulum, in HCC. The 
effects of oprozomib and the role of the UPR were evaluated in HCC cell lines and in 
diethylnitrosamine-induced and xenograft mouse models for HCC. Oprozomib dose-
dependently reduced the viability and proliferation of human HCC cells. Unexpectedly, 
oprozomib-treated cells displayed diminished cytoprotective ATF6-mediated signal 
transduction as well as unaltered PERK and IRE1 signaling. However, oprozomib 
increased pro-apoptotic UPR-mediated protein levels by prolonging their half-life, 
implying that the proteasome acts as a negative UPR regulator. Supplementary 
boosting of UPR activity synergistically improved the sensitivity to oprozomib via 
the PERK pathway. Oral oprozomib displayed significant antitumor effects in the 
orthotopic and xenograft models for HCC, and importantly, combining oprozomib with 
different UPR activators enhanced the antitumor efficacy by stimulating UPR-induced 
apoptosis without cumulative toxicity. In conclusion, next-generation proteasome 
inhibition by oprozomib results in dysregulated UPR activation in HCC. This finding 
can be exploited to enhance the antitumor efficacy by combining oprozomib with 
clinically applicable UPR activators.
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cell-cycle regulation, and, ultimately, apoptosis. Bortezomib 
is the first-in-class proteasome inhibitor clinically used 
for the treatment of multiple myeloma. Bortezomib-
induced cell death is related to induction of endoplasmic 
reticulum (ER) stress, inhibition of nuclear factor kappa B, 
activation of caspase-8 and generation of oxidative stress 
[3, 4]. Multiple clinical trials have demonstrated that this 
small-molecule possesses antitumor activity in a variety 
of human cancers [5, 6]. Despite promising preclinical 
results [5], a multicenter single-arm phase II trial assessing 
the activity of bortezomib in HCC has demonstrated 
modest antitumor effects, indicating intrinsic or acquired 
resistance [4, 7]. In addition, the majority of the patients 
developed important adverse events, including peripheral 
neuropathy [7]. Nevertheless, the good clinical outcome of 
bortezomib in multiple myeloma led to the development of 
next-generation proteasome inhibitors, such as carfilzomib, 
that selectively and irreversibly bind to the proteasome in 
order to enhance its inhibition, improve antitumor activity 
and decrease toxicity by reducing off-target effects [8, 9]. 
A phase III trial showed that intravenously administered 
carfilzomib improved progression-free survival in myeloma 
with a favorable risk-benefit profile [10]. Recently, an orally 
bioavailable analogue of carfilzomib, called oprozomib 
(OZ), was developed [9].
Proteasome inhibition is thought to trigger the 
accumulation of misfolded proteins in the ER, which 
activates the unfolded protein response (UPR) [4]. Three 
major ER stress transducers have been identified: PKR-like 
endoplasmic reticulum kinase (PERK), inositol-requiring 
enzyme-1 (IRE1) and activating transcription factor 6 
(ATF6) [11]. Following release of chaperone glucose-
regulated protein, 78 kDa (GRP78), PERK phosphorylates 
eukaryotic initiation factor 2α (eIF2α) leading to repression 
of global translation. However, the phosphorylated form 
of this factor favors selective translation of activating 
transcription factor 4 (ATF4), which activates genes 
involved in protein quality control, amino acid biosynthesis 
as well as apoptosis regulators such as c/EBP-homologous 
protein (CHOP) [11]. Activation of IRE1 results in 
splicing of unspliced X-box-binding protein 1 (XBP1u) 
mRNA to generate a more active spliced XBP1 (XBP1s), 
which induces genes involved in protein folding such as 
endoplasmic reticulum DnaJ homolog 4 (ERDJ4), protein 
degradation and redox homeostasis [11]. ATF6 is mobilized 
to the Golgi where it is cleaved by regulated intramembrane 
proteolysis (RIP), which involves the site-1 (S1P) and 
site-2 (S2P) proteases, releasing a transcriptionally 
active fragment. This pathway induces the expression of 
chaperones, such as GRP78, glucose-regulated protein, 94 
kDa (GRP94), protein disulfide isomerase A4 (PDIA4), 
calreticulin (CALR) and endoplasmic oxidoreductin-1-
like protein (ERO1L), XBP1u and of proteins stimulating 
protein degradation, such as homocysteine-inducible, 
ER stress-inducible, ubiquitin-like domain member 1 
(HERPUD1) [12].
In this study, we provide a molecular clue to OZ’s 
mode of action and identified the therapeutic potential of 
OZ in monotherapy and in combination with modulators 
of the UPR in vitro and in mouse models for HCC. Finally, 
our data illustrate that the proteasome serves a distinct 
function in restraint of UPR signaling by managing the 
UPR-induced protein turnover.
RESULTS
Supplementary ER stress increases the 
sensitivity of HCC cells to proteasome inhibition 
Here, we aim to assess the effect of OZ alone or 
in combination with UPR modulators on the viability, 
proliferation and executioner caspase-3/7 activity of HCC 
cells. Combination with the chemical ER stress inducer 
tunicamycin, which inhibits N-linked protein glycosylation, 
or with the recently developed small-molecules selectively 
inhibiting the IRE1 or PERK pathway or with salubrinal, 
which inhibits eIF2α dephosphorylation, was evaluated [15]. 
In HepG2 cells, 48 hours of incubation with 100–400 nM 
OZ dose-dependently reduced cell viability, as shown by 
a tetrazolium MTT spectrophotometric assay (p < 0.001; 
Figure 1A and Table S1). Addition of noncytotoxic doses 
of tunicamycin or salubrinal significantly decreased cell 
viability (p < 0.05, combination index (CI) = 0.71 and 0.60, 
respectively; Figure 1A and Tables S1–S2). As shown by 
BrdU incorporation, OZ dose-dependently decreased the 
proliferation rate (p < 0.001 for 400 nM OZ; Figure 1B), and 
the addition of tunicamycin or salubrinal further impeded 
cell proliferation (p < 0.05). OZ induced the activation 
of executioner caspase-3/7 in HepG2 cells (p < 0.001; 
Figure 1C). Again, addition of tunicamycin or salubrinal 
further increased caspase-3/7 activity (p < 0.001). Although 
the IRE1 and PERK inhibitors were previously validated 
[15], these compounds did not affect the sensitivity of HCC 
cells to 100–400 nM OZ in HepG2 cells. Since tunicamycin 
increased the sensitivity but is not clinically applicable 
because of its toxicity, the HIV protease inhibitor nelfinavir, 
which represents one of the few clinically applicable ER 
stress-inducing agents [16], was tested. Interestingly, 
addition of nelfinavir also synergistically increased the 
sensitivity to OZ (CI = 0.68). MTT viability and BrdU 
incorporation experiments were repeated in Huh7 cells with 
similar results (Figure S1A–S1B and Tables S1–S2). These 
results indicate that the sensitivity of human HCC cells to 
oprozomib is increased by ER stress inducers.
Next, we questioned whether the efficacy of 
other proteasome inhibitors, such as the first-in-class 
proteasome inhibitor bortezomib, could also be enhanced 
by combination with UPR inducers. A similar increase 
in antiproliferative efficacy was observed with 25 nM 
bortezomib in combination with tunicamycin, nelfinavir 
or salubrinal in HepG2 cells (Figure S2A–S2B). 
Finally, we assessed whether OZ or bortezomib altered 
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Figure 1: Antiproliferative and pro-apoptotic effects of oprozomib in monotherapy or in combination with modulators 
of ER stress in human hepatoma HepG2 cells. (A) MTT assay (B) BrdU incorporation (C) Caspase-3/7 activity. OZ: oprozomib. *p 
< 0.05, **p < 0.01, ***p < 0.001 compared to oprozomib 0 nM; #p < 0.05, ##p < 0.01, ###p < 0.001 compared to the respective concentration 
of oprozomib alone. Results are representative of 2 independent experiments.
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the chemosensitivity of HepG2 cells to 2.5–10.0 µM 
doxorubicin for 48 h and observed that proteasome 
inhibition did not alter the chemosensitivity (data not 
shown). Together, these results indicate that the sensitivity 
of human HCC cells to proteasome inhibition is enhanced 
by ER stress signaling. In the next experiments, OZ was 
applied at a dose of 400 nM, unless otherwise indicated, 
since this was the concentration at which OZ inhibits the 
proliferation rate by approximately 50% in both HepG2 and 
Huh7 cells.
Antiproliferative effect of oprozomib depends on 
the build-up of proteotoxic stress
In contrast to the growth-inhibitory effects after 
prolonged incubation (48 hours, as stated above), 400 nM 
OZ did not induce a significant alteration in cell viability, 
proliferation rate or caspase-3/7 activity after shorter 
incubation times (8–12 hours, data not shown), suggesting 
that OZ requires sufficient time to build-up proteotoxicity 
in HCC cells. To demonstrate that proteotoxic stress 
caused by OZ originates during de novo protein synthesis, 
cycloheximide was used to inhibit protein synthesis. 
Importantly, treatment with cycloheximide readily increased 
proliferation (p < 0.001; Figure S3A) and cell viability 
(p < 0.01; Figure S3B) and diminished caspase-3/7 activity 
(p < 0.001; Figure S3C) of OZ-challenged HepG2 cells. 
In addition, we found that OZ increased the levels of 
ubiquitin-conjugated proteins and that co-incubation with 
cycloheximide reduced the accumulation of these conjugates 
(Figure S3D).
Because bortezomib generates oxidative stress, 
which is crucial for its antitumor activity [17] and is 
reported to induce ER stress [11], we investigated whether 
the antiproliferative effect of OZ is also dependent on 
oxidative stress. Therefore, we measured cell viability 
and proliferation after treatment with OZ alone or in 
combination with the antioxidants N-acetyl-L-cysteine 
(NAC) or ascorbic acid in HepG2 cells. Surprisingly, 
addition of these antioxidants to OZ did not alter its 
antitumor action (Figure S3A–S3C). Thus, these findings 
suggest that the build-up of proteotoxic, and not oxidative, 
stress is indispensable for the effects of OZ.
Oprozomib inhibits proteasomal degradation of 
UPR-mediated proteins without induction of the 
transcriptional UPR program
Next, we aimed to evaluate the effects of OZ on the 
pattern of UPR signaling in HCC cells. First, we examined 
the induction of UPR targets at the mRNA level by 200 
or 400 nM OZ in HepG2 cells. Surprisingly, incubation 
with 400 nM OZ downregulated the ATF6-mediated 
GRP78 and PDIA4 mRNA levels (p < 0.05; Figure 2A) 
[18]. In addition, incubation with 400 nM OZ repressed 
CHOP and ATF4 transcription (p < 0.05) but did not 
alter the mRNA levels of IRE1-generated XBP1s and its 
target ERDJ4. Even in the presence of ER stress induced 
by tunicamycin, OZ attenuated the effect of ER stress on 
the transcription of GRP78, PDIA4, XBP1u and CHOP. 
Intriguingly, the levels of growth arrest and DNA damage 
inducible 34 (GADD34) mRNA, a downstream target of 
ATF4 and CHOP protein, were increased by incubation 
with OZ and tunicamycin compared to tunicamycin alone 
(p < 0.001). Collectively, these data indicate that OZ 
impedes the transcriptional induction of target genes of 
the ATF6 and PERK pathway without altering the IRE1 
RNase activity.
In contrast to the mRNA levels, 400 nM OZ 
increased the protein levels of GRP78, PDIA4, ATF4 
and CHOP (Figure 2B). In line with its transcriptional 
activation, GADD34 protein levels were also elevated. 
Intrigued by these findings, we determined the protein 
half-life of the transcription factor CHOP in HepG2 
cells by evaluating its time-course in the presence of 
cycloheximide (Figure 2C). The half-life of CHOP protein 
increased from 5.75 hours in vehicle-treated to 12.82 
hours in OZ-treated cells (p < 0.001; Figure 2D). Thus, 
OZ increased the UPR-regulated CHOP protein levels 
by inhibition of its proteasomal degradation and not by 
enhanced de novo synthesis following induction of the 
transcriptional UPR program.
OZ impedes tunicamycin-induced cytoprotective 
ATF6 signaling through direct RIP inhibition
Because OZ increased the levels of full ATF6 
protein without changing the levels of the transcriptionally 
active ATF6 fragment (Figure 2B), the modulatory effect 
of OZ on tunicamycin-mediated activation of ATF6 was 
explored (Figure S4). First, we assessed the effect of OZ 
on the tunicamycin-mediated transcriptional induction of 
additional ATF6-regulated UPR targets, such as GRP94, 
ERO1L, CALR and HERPUD1 mRNA (Figure S4A) 
[12, 18]. As expected, upregulation of all ATF6 targets by 
tunicamycin was evident. Addition of OZ to tunicamycin 
downregulated these selected ATF6 targets. To assess 
the effect of OZ on the RIP, the processing of another 
target of RIP, sterol regulatory element binding protein-1 
(SREBP-1), was examined. Western blotting confirmed the 
accumulation of precursor SREBP-1 in OZ-treated HepG2 
cells (Figure S4B). These results suggest that OZ inhibits 
ATF6 signaling by RIP inhibition.
RIP inhibition could occur either directly by 
inhibition of the S1P or S2P expression or activity or 
indirectly by upregulation of a repressor of protease-
mediated ATF6 activation. OZ did not alter the S1P or 
S2P mRNA levels (Figure S4C), suggesting that OZ 
functions through post-translational RIP inhibition 
without affecting S1P or S2P expression. Nucleobindin 
1 is a reported ATF6 repressor [19]. While tunicamycin 
increased nucleobindin 1 expression, the expression in 
OZ-treated cells was indistinguishable from vehicle-
treated cells (Figure S4B).
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Treatment of HepG2 cells with 25 μM 
1,10-phenanthroline, a metalloprotease-specific S2P 
inhibitor [20], led to accumulation of precursor SREBP-1 
and to the absence of processed SREBP-1 detection and 
did not alter the nucleobindin 1 expression (Figure S4B). 
In addition, 5 to 50 μM of 1,10-phenanthroline dose-
dependently reduced the HepG2 cell viability (Figure S4D), 
phenocopying the effects of OZ (Figure 1 and S4B, 
respectively). Finally, also 1,10-phenanthroline at 25 μM 
did not significantly alter the S2P transcription (Figure 
S4E), suggesting that inhibition of the activity of S2P does 
not affect its expression. Thus, OZ, at an effective dose 
of 400 nM, inhibits tunicamycin-induced cytoprotective 
ATF6 signaling by RIP inhibition likely via direct off-target 
inhibition of S1/S2 protease activity without altering their 
expression.
The PERK pathway regulates the nelfinavir-
mediated increase in sensitivity to OZ
OZ slightly increased the eIF2α phosphorylation, 
which could not be inhibited by the PERK inhibitor 
(Figure 2B), pointing to the involvement of other eIF2α 
kinases, as previously reported for eIF2α phosphorylation 
induced by proteasome inhibitor MG-132 [21]. Importantly, 
addition of salubrinal or nelfinavir profoundly increased 
the OZ-induced eIF2α phosphorylation and pro-apoptotic 
CHOP protein levels (Figure 2B), which may contribute 
to the increased sensitivity to OZ (Figure 1). Indeed, 
addition of the PERK inhibitor increased the proliferation 
rate of HepG2 cells treated with the combination of OZ 
and nelfinavir (p < 0.05; Figure 2E), validating the role of 
the PERK pathway in the mechanism of this combination. 
Addition of the IRE1 inhibitor did not alter the proliferation 
rate (data not shown). Furthermore, addition of nelfinavir 
to OZ abolished the protein levels of the ATF6-dependent 
chaperones GRP78 and PDIA4 (Figure 2B), possibly 
exacerbating the generated proteotoxicity. Interestingly, 
nelfinavir was previously reported to induce apoptosis 
in liposarcoma cells by direct S2P inhibition [22]. These 
data suggest that the PERK pathway activation is a key 
mechanism inducing the enhanced anti-tumor activity of 
OZ following the addition of UPR activators.
OZ reduced tumor burden in orthotopic and 
xenograft mouse models for HCC
Prior to evaluating the antitumor activity of OZ in 
the DEN-induced mouse model characterized by severe 
liver dysfunction [23], different 2-week dosing regimens 
were tested in 25-week saline-treated and DEN-treated 
mice (n = 3, Table 1). We observed high mortality in the 
mice with liver dysfunction treated with 50 mg/kg/day for 
5 consecutive days per week. However, at 30 mg/kg/day 
for 3 consecutive days per week, no mortality occurred. 
Therefore, this dosing regimen was applied in the following 
experiments. 
OZ for 4 weeks did not affect mortality in 25-week 
saline- or DEN-injected mice (n = 12, Table 2). The average 
body weight of mice was lower following 25 weeks of DEN 
compared to saline administration (p < 0.001, Table 2). 
Subsequent treatment with OZ did not alter the average body 
weight compared to vehicle. Although serum ALT and AST 
levels were elevated by DEN administration (p < 0.001), 
treatment with OZ did not alter these levels in the surviving 
mice (Figure S5A).
DEN-treated mice that received OZ developed fewer 
macroscopic nodules per liver (all sizes: 16.2 ± 4.5 after 
vehicle versus 11.1 ± 3.9 after OZ; p < 0.05). HCC burden, 
microscopically quantified by the loss of reticulin staining, 
was reduced in OZ-treated compared to vehicle-treated 
mice (p < 0.01, Figure 3A–3C). Hepatic caspase-3/7 activity 
levels ex vivo, which were elevated by DEN compared to 
saline administration (p < 0.001, Figure 3D), were increased 
following OZ monotherapy compared to vehicle-treated 
HCC-bearing mice (p < 0.05), consistent with in vivo 
apoptosis induction.
Since we previously reported the UPR pattern in the 
DEN-induced mouse model [15], we examined the impact 
of OZ administration on the expression of UPR markers 
in HCC. OZ administration reduced the levels of Grp78 
(p < 0.01) and Chop (p < 0.05) mRNA in the isolated 
tumors (Figure 3E). However, immunoblotting of lysates 
of isolated tumors revealed that OZ was associated with 
higher CHOP protein levels in vivo (Figure 3F). In contrast, 
UPR-regulated caspase-12 cleavage was only slightly 
increased by OZ. These observations provide evidence that 
the efficacy of OZ in inhibiting the growth of DEN-induced 
HCC is through similar mechanisms as those observed 
in vitro.
Secondly, the effect of OZ was assessed in a HepG2 
xenograft model. No significant differences in body weight 
or appearance between control and OZ-treated animals 
were observed during the course of the xenograft study 
(data not shown). OZ administration suppressed the growth 
rate of the HepG2-derived tumors (p < 0.05, Figure 4A). 
Accordingly, TUNEL immunofluorescence demonstrated 
a significant increase of TUNEL-positive apoptotic HepG2 
cells following OZ administration (p < 0.01, Figure 4C–4D).
Nelfinavir and salubrinal potentiate the 
therapeutic efficacy of OZ in experimental HCC
Next, we assessed the effects of supplementary UPR 
activation via nelfinavir and salubrinal on HCC growth 
in vivo. Administration of nelfinavir or salubrinal in mice 
after 25 weeks of DEN induction did not alter the mean 
body weight compared to vehicle (Table 1). Although 
hepatic caspase-3/7 activity was not significantly increased 
(Figure 3D), combining OZ with nelfinavir was more 
efficacious compared to OZ monotherapy in the orthotopic 
model (number of macroscopic nodules per liver: 11.1 ± 3.9 
after OZ versus 7.2 ± 5.2 after OZ and nelfinavir; 
microscopic tumor burden: p < 0.05; Figure 3A–3C). 
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Figure 2: Oprozomib modulates the UPR pattern in HepG2 cells. (A) Real-time PCR analysis of relative mRNA levels of UPR-
mediated genes after 48 hours of incubation with the indicated treatments. (B) Immunoblotting of UPR-mediated proteins. (C) To measure 
the half-life of CHOP protein in HepG2 cells, cells were pre-treated for 1 hour with 1 μg/ml tunicamycin and a time-course in the presence 
of 50 μg/ml cycloheximide, which blocks protein synthesis, was performed. Band intensities were quantified using ImageJ software. 
(D) Half-life of CHOP protein was determined by plotting optical density (arbitrary unit) calculated from densitometric analysis of bands 
in panel C versus hours of treatment. Data represent the mean ± SD of three independent experiments. (E) BrdU incorporation of HepG2 
cells incubated with indicated treatments for 48 hours. OZ: 400 nM oprozomib. *p < 0.05, **p < 0.01, ***p < 0.001.
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Addition of salubrinal at 1 mg/kg/24 hours similarly 
improved the effect of OZ (number of macroscopic nodules 
per liver: 6.7 ± 4.8 after OZ and salubrinal; microscopic 
tumor burden: p < 0.05; Figure 3A–3C). Interestingly, 
addition of nelfinavir or salubrinal to OZ promoted eIf2α 
phosphorylation and downstream Chop mRNA and protein 
levels (Figure 3E–3F), suggesting intensified pro-apoptotic 
UPR signaling. Caspase-12 cleavage was indeed markedly 
increased by the addition of nelfinavir or salubrinal to OZ 
treatment (Figure 3F), confirming the pronounced induction 
of UPR-triggered apoptosis. In contrast, salubrinal at 
1 mg/kg/72 hours induced no detectable effects on the 
antitumor efficacy of OZ, eIf2α phosphorylation or Chop 
expression (data not shown).
Accordingly, in the HepG2 xenograft model, dual 
therapy with OZ and nelfinavir or OZ and salubrinal 
effectively inhibited tumor growth compared to vehicle-
treated (both p < 0.001) and OZ-treated mice (both 
p < 0.01) (Figure 4A), whereas nelfinavir or salubrinal 
monotherapy did not alter the xenograft growth (Figure 
S5B–S5C). Furthermore, addition of nelfinavir or salubrinal 
augmented the number of TUNEL-positive HepG2 cells 
in the xenograft tumors compared to OZ monotherapy 
(p < 0.05 and p < 0.01, respectively, Figure 4C–4D), 
suggesting robust induction of apoptosis when UPR 
modulators are added. Thus, we identified that nelfinavir 
and salubrinal potentiate the therapeutic efficacy of OZ in 
different models for HCC, likely through increased UPR-
mediated apoptosis via induction of Chop synthesis while 
OZ diminishes its proteasomal degradation (Figure 5).
DISCUSSION
Proteasome inhibition could represent a novel 
therapeutic strategy for advanced HCC [5, 7]. The next-
generation orally bio-available irreversible proteasome 
inhibitor oprozomib (OZ) is assumed to evoke fewer 
adverse events and improve antitumor activity compared 
to the first-in-class proteasome inhibitor bortezomib 
[3]. Recently, OZ was shown to reduce tumor growth in 
myeloma and head and neck cancer xenograft models [3]. 
In this study, OZ exerted potent antitumor effects in vitro 
and in different in vivo models for HCC, supporting the 
potential value of irreversibly targeting the proteasome in 
the treatment of HCC. Moreover, we revealed a strategy to 
enhance the efficacy of OZ through modulation of the UPR.
When unfolded proteins accumulate in the ER, the 
UPR is initiated to allow the cells to restore homeostasis 
through proteasomal degradation of unfolded proteins, 
translational arrest and promoting protein folding capacity 
[11]. The association between UPR activity and therapeutic 
efficacy of proteasome inhibition was first illustrated 
in myeloma, in which patient serum levels of XBP1 
correlated with the clinical response towards bortezomib 
[24]. Theoretically, decreased protein degradation by 
proteasome inhibition could lead to oxidative stress and 
UPR activation. However, the effect on the UPR is not 
well understood. We showed that the cytotoxic effect of 
OZ depends on the build-up of proteotoxic stress without 
an important contribution of oxidative stress. Although 
OZ did not induce the transcriptional UPR program and 
Table 1: Mortality at different dosing regimens (n = 3 in each group)
Consecutive-day dosing in weekly cycle Mortality in saline-treated mice Mortality in DEN-treated mice
50 mg/kg/day for 5 days 2/3 3/3
30 mg/kg/day for 5 days 1/3 1/3
30 mg/kg/day for 4 days 0/3 1/3
30 mg/kg/day for 3 days 0/3 0/3
Table 2: Average body weight (g) ± SD and survival of mice (n = 12 in each group)
Group Average body weight 25 weeks (g) Average body weight 29 weeks (g) Survival(%)
Saline => vehicle 27.22 ± 1.32 26.03 ± 1.61 100
DEN => vehicle 19.75 ± 1.76*** 18.30 ± 2.92 58.33
DEN => OZ 20.86 ± 1.45 19.17 ± 2.10 NS 58.33
DEN => OZ + nelfinavir 22.96 ± 3.65 17.92 ± 3.19 NS 66.67
DEN => OZ + salubrinal 21.23 ± 5.89 18.09 ± 6.23 NS 66.67
***p < 0.001: 25 weeks DEN vs. saline, NS= not significant compared to vehicle.
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Figure 3: Impact of oprozomib in monotherapy or in combination with ER stress modulators on an orthotopic and 
a xenograft model for HCC. (A) Photographs of representative livers after different treatments. (B) Reticulin staining. Scale bar: 
100 µm. (C) Assessment of tumor burden in the carcinogen-induced mouse model in randomly selected high-power fields. (D) Hepatic 
caspase-3/7 activity ex vivo. Values represent the mean ± SD. (E) Real-time PCR analysis and (F) Immunoblotting of UPR targets in 
isolated DEN-induced tumors following the indicated treatments. Densitometric analysis relative to tubulin is indicated below. *p < 0.05, 
**p < 0.01, ***p < 0.001.
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even inhibited the protease-dependent activation of the 
cytoprotective ATF6 pathway, OZ increased the protein 
levels of different UPR markers. Notably, OZ increased 
the protein stability of the pro-apoptotic transcription 
factor CHOP and induced transcription of GADD34. Thus, 
OZ increased the levels of the UPR-regulated proteins 
by decreasing their proteasomal degradation rather than 
generally activating the UPR program due to increased 
unfolded protein load. Apparently, rapid proteasomal 
degradation of UPR effector proteins is a negative feedback 
mechanism following recovery of ER proteostasis.
Consistent with the effect of OZ on the UPR, PERK 
or IRE1 inhibition did not alter its effect, whereas ER stress 
inducers, such as tunicamycin or nelfinavir, or an inhibitor 
of eIF2α dephosphorylation enhanced the growth-inhibitory 
effects of OZ in HCC cells. Interestingly, a similar synergy 
was observed with bortezomib, suggesting this concept can 
also be applied to other proteasome inhibitors. Because the 
Figure 4: Oprozomib and UPR modulation in experimental HCC. (A) Evolution of tumor volume in mice bearing HepG2-
derived xenograft tumors. (B) Final tumor weights. (C) TUNEL immunofluorescence in HepG2 xenografts and (D) quantification of 
TUNEL-positive index (n = 6). OZ: oprozomib. Values represent the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.
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maximum serum levels attained in patients are much higher 
(bortezomib: 0.16 μM (1.3 mg/m2 intravenous); oprozomib: 
3.8 μM (30 mg per os) [25]), the concentrations used 
in vitro are clinically relevant.
Based on these results, we evaluated the in vivo 
effects of the combination of nelfinavir or salubrinal and 
OZ in HCC. Both nelfinavir and salubrinal enhanced the 
growth-inhibitory effect without cumulative toxicity, 
suggesting this rational combination presents a safe 
strategy to potentiate the antitumor effects of proteasome 
inhibition in HCC. Experience in the use of proteasome 
inhibitors and nelfinavir in clinical practice and the 
oral bio-availability are considerable advantages for 
implementation. 
Bortezomib resistance in myeloma cells was 
previously linked to eIF2α phosphorylation [26]. Salubrinal 
typically induces enhanced resistance to stress conditions, 
such as those triggered by oxidizing or UPR-activating 
agents [27, 28]. However, here we provide evidence 
that salubrinal renders HCC cells more susceptible to 
OZ-mediated proteasome inhibition by stimulating the 
PERK/phospho-eIF2α/CHOP pathway. Of note, human 
HCC, in contrast to unaffected adjacent liver tissue, is 
characterized by increased CHOP staining [29], suggesting 
that tumor-selective effects can be achieved. Additionally, 
we previously reported the high expression of Chop in 
the HCC nodules compared to the non-HCC tissue of the 
DEN-induced mouse model [15].
Although a recent phase I trial with OZ demonstrated 
that OZ has an acceptable safety profile when given daily 
for 5 consecutive days every 2 weeks in patients with solid 
tumors [30], significant toxicity occurred when OZ was 
administered for several consecutive days in mice with 
DEN-induced liver dysfunction. However, identification of 
sensitivity enhancers by UPR modulation could allow for 
a reduction of dose and dose-related toxicity. Because ER 
stress potentiates the antitumor efficacy of OZ, we speculate 
that OZ exerts a stronger effect on hypoxic ER-stressed 
tumor cells compared to the normal liver tissue [15]. 
Consequently, OZ could be more efficacious in combination 
with antiangiogenic treatments promoting tumor hypoxia-
induced UPR [11, 31].
In conclusion, dysregulation of the transcriptional 
UPR program and reduced proteasomal degradation of 
pro-apoptotic UPR-mediated proteins are involved in OZ-
induced cell death. Moreover, modulation of the interplay 
Figure 5: Schematic model outlining the mechanisms of oprozomib with indication of the point of action of the applied 
products. Persistent ER stress activates the tripartite UPR-mediated transcriptional program followed by translation of these UPR proteins, 
which leads to proteotoxicity-mediated tumor cell death. Although oprozomib did not induce the UPR and even inhibited ATF6-mediated 
transcription, it increased the UPR-mediated protein levels by prolonging their half-life. This UPR dysregulation allows for enhanced 
proteotoxicity through supplementary boosting PERK activity by tunicamycin, nelfinavir (also inhibits ATF6) or salubrinal.
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between OZ and the UPR enhances its antitumor efficacy 
without cumulative toxicity. Therefore, OZ monotherapy or 
OZ in combination with an UPR modulator may present a 
novel and clinically applicable therapeutic strategy for HCC.
MATERIALS AND METHODS
Cell culture
HepG2 (ATCC, Virginia, USA) and Huh7 cells 
(JCRB, Japan) were cultured in Dulbecco’s Modified Eagle’s 
medium supplemented with 10% fetal bovine serum (Life 
Technologies, Ghent, Belgium). Cells were incubated for 
48 hours with oprozomib (100–400 nM; ApexBio, USA), 
tunicamycin (1 μg/mL; Sigma, Diegem, Belgium), PERK 
inhibitor (14 μM; GSK2656157, Chengdu novi, Shandong, 
China), salubrinal (50 μM; Sigma), IRE1 inhibitor (25 μM; 
4 μ8C, Calbiochem, Massachusetts, USA), cycloheximide 
(5 μM; Sigma), 1,10-phenanthroline (5–50 μM; Sigma), 
ascorbic acid (50 μM; Sigma), nelfinavir (10 μM; Sigma), 
doxorubicin hydrochloride (2.5–10.0 µM; Sigma) or pre-
treated with N-acetyl-L-cysteine (2 hours; 5 μM; Sigma) 
and compared to equal volumes of solvent as control. Each 
condition was performed in quadruplicate.
Animals
Wild-type 129S2/SvPasCrl mice were purchased from 
Charles River, Belgium, and were housed as previously 
described [13]. The animals had free access to water and 
to a commercial chow (standard maintenance chow, Pavan 
Service-Carfil, Oud-Turnhout, Belgium). Five-week-old 
male mice received weekly intraperitoneal injections with 
saline or diethylnitrosamine (DEN) (35 mg/kg, Sigma) for 
25 weeks. Then, 4 DEN-treated groups (n = 12 for each 
group) were treated for 4 weeks with oprozomib (intragastric 
30 mg/kg/day for 3 consecutive days per week) alone or in 
combination with salubrinal (intraperitoneally 1 mg/kg/day) 
or nelfinavir (intraperitoneally 250 mg/kg/day) and compared 
to a similar volume of vehicle. Blood was collected from 
the retro-orbital sinus under isoflurane anesthesia. After 
macroscopic evaluation and quantification of the number 
of hepatic tumors, all organs were fixed in 4% phosphate-
buffered formaldehyde (Klinipath, Olen, Belgium) and 
embedded in paraffin or snap frozen in liquid nitrogen. 
Hematoxylin/eosin and reticulin staining were performed to 
assess tumor burden, and the results were blindly evaluated 
by two independent observers (CC and YV).
For the xenograft model, HepG2 cells (6 × 106) were 
suspended in 100 µl serum-free media and mixed with 
100 µl Matrigel (BD Biosciences, Bedford, MA, USA). 
Cell/Matrigel mixture was injected subcutaneously into 
the right flank of 8-week-old athymic nude (Foxn1nu/
Foxn1nu) mice housed in filter-topped cages. Tumor 
dimensions were recorded three times per week with a 
digital caliper starting with the first day of treatment. Tumor 
volumes were calculated using the following formula: 
volume (mm³) = ab²/2, where b was the smaller dimension. 
When tumors reached 150 mm³, animals were randomized 
into four groups (n = 6) to receive the same treatment 
regimens as the DEN-treated mice plus monotherapy with 
salubrinal (intraperitoneally 1 mg/kg/day) or nelfinavir 
(intraperitoneally 250 mg/kg/day). The ethical committee 
of experimental animals at Ghent University approved the 
protocols (ECD 13/39).
Detailed information of MTT, TUNEL, caspase-3/7 
activity, bromodeoxyuridine (BrdU) incorporation assays, 
total RNA extraction, quantitative real-time PCR and 
Western blotting is provided in the Supplementary Materials 
and Methods.
Statistics
Statistical analyses were performed using SPSS 
21 (SPSS, Chicago, USA). Data are presented as the 
mean ± SD or percentage relative to controls. Variables 
were tested for normality using the Shapiro-Wilk test. 
Normally distributed data were subjected to the unpaired 
Student’s t-test. Data involving more than two groups 
were assessed by one-way analysis of variance (ANOVA) 
with Bonferroni’s post-hoc test. Non-normally distributed 
data were tested using the Mann-Whitney U test. The chi-
squared test was used to compare mortality. The IC50 
values were obtained using the Bliss method. Interpretation 
of CI values, as calculated by the method of Chou and 
Talalay [14] using CompuSyn software (ComboSyn Inc., 
Paramus, NJ, USA), is defined such that CI = 1 indicates an 
additive effect, and CI < 1 and CI > 1 indicate synergism 
and antagonism, respectively. Reported p-values were two-
sided and considered significant when less than 0.05.
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